Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$30.12 -0.88%

-$0.15 today

Market cap
$3.42B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 1.49M

Average 2.86M

VRDN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Viridian Therapeutics, Inc.NASDAQ: VRDN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q2 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 99.6%, down 0.4 pp year over year. Over 3 fiscal years it widened by 0.0 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
LTMJun 2026
99.6%-0.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+0.0 pp——
3 years+0.0 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How VRDN compares with its peers on the latest reported figures

  • VRDN's LTM Jun 2026 gross margin of 99.6% is the highest of the 4 companies compared; the peer median is 76.5%.
  • Its year-over-year change of -0.4 pp is the highest of 4, against a peer median of -16.8 pp.
  • Over three fiscal years its change of +0.0 pp compares with a peer median of +4.8 pp.
VRDN Competitors Peer median
Gross Margin for VRDN and competitors
Company Period LTM level YoY 3-year change
VRDNViridian Therapeutics, Inc.LTM Jun 202699.6% -0.4 pp+0.0 pp
OCULOcular Therapeutix, Inc.LTM Mar 202687.2% -3.4 pp-3.9 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202676.5% -16.8 pp+13.5 pp
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-360.9% -377.1 pp—
Peer median (excluding VRDN) 76.5%-16.8 pp+4.8 pp

Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.96M1.77M314K302K70.85M
Cost of Revenue00000
Gross Profit2.96M1.77M314K302K70.85M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development56.89M100.89M159.77M238.25M338.93M
Selling, General & Admin25.81M35.18M95M61.08M95.32M
Operating Expenses82.69M136.08M254.76M299.34M434.24M
Depreciation & Amortization120K255K522K540K460K
EBITDA(79.29M)(129.13M)(235.37M)(266.36M)(337.19M)
EBITDA Margin-2676.0%-7287.4%-74957.0%-88199.7%-475.9%
Operating Income(79.73M)(134.3M)(254.45M)(299.04M)(363.4M)
Operating Margin-2690.8%-7579.2%-81035.0%-99018.2%-512.9%
Interest Income318K4.92M18.56M32.13M27.4M
Interest Expense3K486K1.85M3.05M4.95M
Other Income / Expenses315K4.43M16.72M29.09M20.79M
Income Before Tax(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Pre-Tax Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
Income Tax Expense00000
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Net Margin-2680.2%-7329.2%-75711.5%-89387.1%-483.6%
EPS (Basic)(6.66)(3.91)(5.31)(3.98)(3.32)
EPS (Diluted)(6.66)(3.91)(5.31)(3.98)(3.32)
Weighted Avg Shares11.92M32.09M44.76M67.89M84.8M
Weighted Avg Shares (Diluted)11.92M32.09M44.76M67.89M84.8M

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Intrinsic Alpha fair value

Locked

Current Price

$30.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.